| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1027695431 |
| P356 | DOI | 10.1038/NATURE12205 |
| P3181 | OpenCitations bibliographic resource ID | 1153025 |
| P698 | PubMed publication ID | 23698361 |
| P5875 | ResearchGate publication ID | 236932292 |
| P50 | author | Alfred Wittinghofer | Q110588 |
| Herbert Waldmann | Q1609256 | ||
| Gemma Triola | Q30503863 | ||
| Stephan Hahn | Q56850416 | ||
| Shehab A Ismail | Q59543248 | ||
| P2093 | author name string | Nachiket Vartak | |
| Philippe I H Bastiaens | |||
| Anchal Chandra | |||
| Gunther Zimmermann | |||
| Björn Papke | |||
| Maike Hoffmann | |||
| P2860 | cites work | An ARL3-UNC119-RP2 GTPase cycle targets myristoylated NPHP3 to the primary cilium | Q24297497 |
| UNC119 is required for G protein trafficking in sensory neurons | Q24305723 | ||
| Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13 | Q27655405 | ||
| Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo | Q27675096 | ||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity | Q27678097 | ||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation | Q27678948 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination | Q33260141 | ||
| Global analysis of time correlated single photon counting FRET-FLIM data | Q33429902 | ||
| Targeting protein prenylation for cancer therapy | Q33679239 | ||
| Therapeutic intervention based on protein prenylation and associated modifications | Q33943379 | ||
| Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation | Q34101919 | ||
| A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. | Q34178953 | ||
| Imaging biochemistry inside cells | Q34228151 | ||
| An orthosteric inhibitor of the Ras-Sos interaction | Q35854216 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins | Q39426327 | ||
| In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays | Q39706047 | ||
| Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity | Q40543716 | ||
| Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer | Q41454824 | ||
| Multiple Cellular Proteins Modulate the Dynamics of K-ras Association with the Plasma Membrane | Q42364777 | ||
| Photoreceptor cGMP Phosphodiesterase δ Subunit (PDEδ) Functions as a Prenyl-binding Protein | Q44619466 | ||
| Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. | Q52826734 | ||
| RAS oncogenes: the first 30 years. | Q55036584 | ||
| Synthesis of the Rheb and K-Ras4B GTPases | Q57006918 | ||
| P433 | issue | 7451 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | KRAS proto-oncogene, GTPase | Q4042017 |
| P304 | page(s) | 638-42 | |
| P577 | publication date | 2013-05-30 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | |
| P478 | volume | 497 |
| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q90134538 | A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas |
| Q35689539 | A Homogenous Bioluminescent System for Measuring GTPase, GTPase Activating Protein, and Guanine Nucleotide Exchange Factor Activities |
| Q35082125 | A Homology Based Model and Virtual Screening of Inhibitors for Human Geranylgeranyl Transferase 1 (GGTase1). |
| Q54989340 | A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology |
| Q51179388 | A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. |
| Q28547072 | A Pan-GTPase Inhibitor as a Molecular Probe |
| Q37724940 | A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer |
| Q40125605 | A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells |
| Q27314644 | A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion |
| Q35078290 | A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin |
| Q34004748 | A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein |
| Q42216847 | A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes. |
| Q52570601 | A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. |
| Q64277436 | A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer |
| Q33776835 | ALK-rearrangements and testing methods in non-small cell lung cancer: a review |
| Q57023929 | ARL3 Mutations Cause Joubert Syndrome by Disrupting Ciliary Protein Composition |
| Q48583910 | Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers |
| Q38222722 | Activated K-RAS and its effect on morphological appearance. |
| Q27308683 | Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. |
| Q38363739 | Adaptive stress signaling in targeted cancer therapy resistance |
| Q35620999 | Alternative modulation of protein-protein interactions by small molecules |
| Q89410953 | An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth |
| Q41525845 | Analysis of K-Ras Interactions by Biotin Ligase Tagging. |
| Q45973721 | Anticancer drugs: A new approach for blocking KRAS. |
| Q36703469 | Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway |
| Q97525759 | BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy |
| Q55618585 | BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. |
| Q27006853 | Beyond BRAF: where next for melanoma therapy? |
| Q57024518 | Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs |
| Q36084191 | Biosynthesis-driven structure-activity relationship study of premonensin-derivatives |
| Q26740619 | Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment |
| Q42734596 | Cancer: Drug for an 'undruggable' protein |
| Q34225871 | Change or die: targeting adaptive signaling to kinase inhibition in cancer cells |
| Q37598923 | Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation |
| Q36477762 | Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations |
| Q40989800 | Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. |
| Q35590750 | Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme |
| Q35109213 | Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines |
| Q34768090 | Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines |
| Q33622690 | Comprehensive pharmacological profiling of neurofibromatosis cell lines |
| Q38612789 | Computational allosteric ligand binding site identification on Ras proteins. |
| Q47333014 | Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting |
| Q33746220 | Copper-Catalyzed Electrophilic Amination of Heteroaromatic and Aromatic C-H Bonds via TMPZnCl•LiCl Mediated Metalation |
| Q43144651 | Copper-catalyzed electrophilic amination of heteroarenes and arenes by C-H zincation |
| Q38534932 | Current status of the development of Ras inhibitors |
| Q52331924 | Cyclase-Associated Protein 1 (CAP1) is a prenyl-binding partner of Rap1 GTPase. |
| Q40003054 | Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis |
| Q38837319 | Defeat mutant KRAS with synthetic lethality |
| Q100156064 | Deltarasin binds PDE6D |
| Q51119632 | Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer |
| Q51347239 | Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site. |
| Q91912420 | Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism |
| Q38840605 | Development of an image-based screening system for inhibitors of the plastidial MEP pathway and of protein geranylgeranylation |
| Q38641292 | Development of substrate-derived mechanistic sirtuin inhibitors with potential anti-cancer activity |
| Q38608107 | Direct Modulation of Small GTPase Activity and Function |
| Q49721819 | Direct inhibition of RAS: Quest for the Holy Grail? |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q39028691 | Direct targeting of Rab-GTPase-effector interactions |
| Q64233821 | Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding |
| Q35863269 | Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides |
| Q27332168 | Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis |
| Q87434753 | Drug developers refocus efforts on RAS |
| Q43533508 | Drug discovery: Pocket of opportunity |
| Q39182842 | Drugging RAS: Know the enemy |
| Q38891257 | Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view |
| Q35163434 | Drugging the undruggable RAS: Mission possible? |
| Q39228711 | EGF receptor family: twisting targets for improved cancer therapies |
| Q91969105 | EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells |
| Q47443285 | Efforts to Develop KRAS Inhibitors |
| Q35889317 | FRAP, FLIM, and FRET: Detection and analysis of cellular dynamics on a molecular scale using fluorescence microscopy |
| Q36237636 | Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions |
| Q46078887 | Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. |
| Q44951464 | Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. |
| Q90357653 | From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers |
| Q34664265 | GLOBIN-5-dependent O2 responses are regulated by PDL-1/PrBP that targets prenylated soluble guanylate cyclases to dendritic endings |
| Q92156695 | Galectin-8 binds to the Farnesylated C-terminus of K-Ras4B and Modifies Ras/ERK Signaling and Migration in Pancreatic and Lung Carcinoma Cells |
| Q35657842 | Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer |
| Q50154920 | Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis |
| Q38225040 | Genetic, structural, and molecular insights into the function of ras of complex proteins domains. |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q26781443 | Genomic alterations in pancreatic cancer and their relevance to therapy |
| Q57165768 | Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts |
| Q93045200 | Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins |
| Q41884410 | Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains |
| Q38218298 | Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy |
| Q37113976 | How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization |
| Q47155582 | Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells |
| Q27861954 | Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites |
| Q27319610 | Identification of pyrazolopyridazinones as PDEδ inhibitors |
| Q27684047 | In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C |
| Q26782145 | Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy |
| Q45964059 | Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. |
| Q50025866 | Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity |
| Q35624144 | Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides |
| Q35859222 | Inhibitors of Ras-SOS Interactions |
| Q39361391 | Intrinsic protein disorder in oncogenic KRAS signaling |
| Q92100763 | Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry |
| Q38718630 | Investigation of the mutagenic and genotoxic activities of LLL-3, a STAT3 inhibitor. |
| Q97423594 | Iron-Catalyzed Acceptorless Dehydrogenative Coupling of Alcohols With Aromatic Diamines: Selective Synthesis of 1,2-Disubstituted Benzimidazoles |
| Q26766684 | K-Ras protein as a drug target |
| Q89516473 | KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? |
| Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
| Q27007866 | KRAS as a Therapeutic Target |
| Q37709450 | KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies |
| Q26765353 | KRAS oncogene in lung cancer: focus on molecularly driven clinical trials |
| Q38175666 | KRAS: feeding pancreatic cancer proliferation |
| Q60925516 | KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer |
| Q34659332 | Kras as a key oncogene and therapeutic target in pancreatic cancer |
| Q37301995 | Lessons from computer simulations of Ras proteins in solution and in membrane |
| Q92128564 | MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells |
| Q35351594 | Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region |
| Q58098402 | Modeling and subtleties of K-Ras and Calmodulin interaction |
| Q58694841 | Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer's disease |
| Q41461306 | Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS. |
| Q41821421 | Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors. |
| Q40783185 | Molecular docking and simulation of Curcumin with Geranylgeranyl Transferase1 (GGTase1) and Farnesyl Transferase (FTase). |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q33819193 | Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL |
| Q90573177 | Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition |
| Q35213124 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer |
| Q37409321 | Mutant KRAS is a druggable target for pancreatic cancer |
| Q33716297 | Mutant KRAS promotes malignant pleural effusion formation |
| Q50130460 | Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion. |
| Q40963810 | Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I. |
| Q52666594 | New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. |
| Q35051540 | Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers |
| Q41161853 | Novel Biochemical and Structural Insights into the Interaction of Myristoylated Cargo with Unc119 Protein and Their Release by Arl2/3. |
| Q55070034 | Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. |
| Q42198469 | Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity |
| Q34113460 | Oncogenic KRAS signalling in pancreatic cancer |
| Q37678092 | Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix |
| Q38195457 | Oncogenic protein interfaces: small molecules, big challenges. |
| Q47975744 | One-pot strategy of copper-catalyzed synthesis of 1,2-disubstituted benzimidazoles |
| Q28650700 | Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines |
| Q92760997 | PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity |
| Q27704536 | PDE6δ-mediated sorting of INPP5E into the cilium is determined by cargo-carrier affinity |
| Q64993325 | PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. |
| Q30080017 | PI3K and cancer: lessons, challenges and opportunities |
| Q40136040 | Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. |
| Q38396634 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies |
| Q92504704 | Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches |
| Q38568187 | Pharmacological Inhibition of Protein Lipidation |
| Q58577211 | Pharmacological targeting of RAS: Recent success with direct inhibitors |
| Q47758406 | Plasma membrane phosphatidylinositol 4-phosphate and 4,5-bisphosphate determine the distribution and function of K-Ras4B but not H-Ras proteins. |
| Q36765168 | Plasma membrane regulates Ras signaling networks |
| Q47223139 | Posttranslational Modifications of RAS Proteins. |
| Q35702897 | Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. |
| Q34737521 | Preclinical efficacy of MEK inhibition in Nras-mutant AML. |
| Q64055869 | Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma |
| Q28610567 | Progress in Making Ras as a Druggable Target |
| Q92861450 | Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection |
| Q88964866 | Protein Lipidation in Cell Signaling and Diseases: Function, Regulation, and Therapeutic Opportunities |
| Q38704283 | Protein prenylation: unique fats make their mark on biology |
| Q91162949 | Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway |
| Q35397776 | Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays |
| Q35824701 | Protein-protein interactions as drug targets |
| Q28554516 | PubMedPortable: A Framework for Supporting the Development of Text Mining Applications |
| Q38686612 | Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells |
| Q90588953 | Quantifying Ligand-Protein Binding Kinetics with Self-Assembled Nano-oscillators |
| Q39407402 | RAS Proteins and Their Regulators in Human Disease |
| Q28070394 | RAS isoforms and mutations in cancer at a glance |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q33646519 | Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target |
| Q52721338 | Ras and Rap1: A tale of two GTPases. |
| Q38192416 | Ras and autophagy in cancer development and therapy. |
| Q49921459 | Ras and the Plasma Membrane: A Complicated Relationship |
| Q35151374 | RasG signaling is important for optimal folate chemotaxis in Dictyostelium |
| Q27318713 | Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. |
| Q38364681 | Recent advances in combinatorial biosynthesis for drug discovery |
| Q48246978 | Recent advances in the biology and therapy of medullary thyroid carcinoma. |
| Q99616637 | Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q53676358 | Selective Targeting of the KRAS Codon 12 Mutation Sequence by Pyrrole-Imidazole Polyamide seco-CBI Conjugates. |
| Q35981250 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge |
| Q48192786 | Small-Molecule Inhibition of the UNC119-Cargo Interaction |
| Q57169171 | Small-Molecule Modulation of Lipid-Dependent Cellular Processes against Cancer: Fats on the Gunpoint |
| Q35188280 | Small-molecule modulation of Ras signaling |
| Q34410212 | Smarter drugs emerging in pancreatic cancer therapy |
| Q42782864 | Sorting of lipidated cargo by the Arl2/Arl3 system |
| Q41107898 | Spatial cycles mediated by UNC119 solubilisation maintain Src family kinases plasma membrane localisation |
| Q57006658 | Specificity of Lipoprotein Chaperones for the Characteristic Lipidated Structural Motifs of their Cognate Lipoproteins |
| Q54137051 | Sphingomyelin metabolism is a regulator of KRAS function. |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q35738960 | State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors |
| Q27682798 | Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy |
| Q37398069 | Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ. |
| Q28833740 | Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK |
| Q42645888 | Survival of pancreatic cancer cells lacking KRAS function. |
| Q38543525 | Switching off malignant pleural effusion formation-fantasy or future? |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
| Q47336772 | TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis |
| Q55015991 | Targeted Therapies for Pancreatic Cancer. |
| Q42431459 | Targeted therapies for lung cancer: how did the game begin? |
| Q33361738 | Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? |
| Q37246286 | Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer |
| Q35187475 | Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives |
| Q36398758 | Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. |
| Q49167162 | Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics |
| Q38423044 | Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? |
| Q39163561 | Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q38267209 | Targeting RAS-mutant cancers: is ERK the key? |
| Q47989097 | Targeting Ras with Macromolecules |
| Q48195145 | Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. |
| Q30597330 | Targeting pathways downstream of KRAS in lung adenocarcinoma |
| Q36320570 | Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy |
| Q39367990 | Targeting the K-Ras/PDEδ protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage? |
| Q92048149 | Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors |
| Q64064543 | The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression |
| Q43113930 | The N- and C-terminal ends of RPGR can bind to PDE6δ. |
| Q39071250 | The RAS-Effector Interaction as a Drug Target |
| Q36669604 | The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding |
| Q34490200 | The dynamic control of signal transduction networks in cancer cells |
| Q46493680 | The potential of targeting Ras proteins in lung cancer |
| Q58078881 | The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo |
| Q37122874 | Therapeutic Approaches to RAS Mutation |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
| Q41915120 | Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor |
| Q37660073 | Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers |
| Q41832373 | Tumors topple when ERKs uncouple. |
| Q59791944 | UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras |
| Q46929162 | US National Cancer Institute's new Ras project targets an old foe. |
| Q63383507 | Visualizing biologically active small molecules in cells using click chemistry |
| Q90160716 | Weak membrane interactions allow Rheb to activate mTORC1 signaling without major lysosome enrichment |
| Q47566725 | Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition |
| Q47252585 | eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs |
| Q38742653 | miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3 |
Search more.